American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Jul 2024
Editorial Comment LetterResilience and Stress Are Heterogenic Too, We Should Act Accordingly.
-
Am. J. Respir. Crit. Care Med. · Jul 2024
Editorial CommentCan a Rat Breathe through a Mouse's Lung?
-
Am. J. Respir. Crit. Care Med. · Jul 2024
Characterization and Mortality Risk of Impaired Left Ventricular Filling in COPD.
In COPD, impaired left ventricular (LV) filling might be associated with coexisting HFpEF or due to reduced pulmonary venous return indicated by small LV size. We investigate the all-cause mortality associated with small LV or HFpEF and clinical features discriminating between both patterns of impaired LV filling. ⋯ In COPD, both small LV and HFpEF-features are associated with increased all-cause mortality and represent two distinct patterns of impaired LV filling This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).
-
Am. J. Respir. Crit. Care Med. · Jul 2024
Multicenter StudyAirway 'Resistotypes' and Clinical Outcomes in Bronchiectasis.
Rationale: Chronic infection and inflammation shapes the airway microbiome in bronchiectasis. Utilizing whole-genome shotgun metagenomics to analyze the airway resistome provides insight into interplay between microbes, resistance genes, and clinical outcomes. Objectives: To apply whole-genome shotgun metagenomics to the airway microbiome in bronchiectasis to highlight a diverse pool of antimicrobial resistance genes: the "resistome," the clinical significance of which remains unclear. ⋯ Successful targeted eradication in P. aeruginosa-colonized individuals mediated reversion from RT2 to RT1, a more clinically favorable resistome profile demonstrating reduced resistance gene diversity. Conclusions: The bronchiectasis resistome associates with clinical outcomes, geographic origin, and the underlying host microbiome. Bronchiectasis resistotypes link to clinical disease and are modifiable through targeted antimicrobial therapy.